(A19_067_2015_0670001_1024) A19_067_2015_0670001_1024 (Q2167250): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Changed label, description and/or aliases in 2 languages: Changing unique label-description pair) |
||
| description / en | description / en | ||
Project in Italy | Project Q2167250 in Italy | ||
| description / it | description / it | ||
Progetto in Italia | Progetto Q2167250 in Italia | ||
Revision as of 06:49, 3 November 2020
Project Q2167250 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | (A19_067_2015_0670001_1024) A19_067_2015_0670001_1024 |
Project Q2167250 in Italy |
Statements
73,125.0 Euro
0 references
325,000.0 Euro
0 references
22.5 percent
0 references
1 October 2015
0 references
13 May 2019
0 references
22 March 2021
0 references
CNR - CONSIGLIO NAZIONALE DELLE RICERCHE - ISTITUTO DI FISIOLOGIA CLINICA
0 references
43°42'57.38"N, 10°24'6.70"E
0 references
IL PROGETTO MIRA A SUPERARE CRITICITA TECNOLOGICHE NELLO SVILUPPO DI NUOVE STRATEGIE DIAGNOSTICHE E TERAPEUTICHE PER PATOLOGIE A ELEVATO IMPATTO SOCIALE, COME MELANOMA E SCLEROSI MULTIPLA. L?IDEA SI BASA SULLO SVILUPPO DI NUOVE TECNICHE DI INGEGNERIZZAZIONE CELLULARE E/O SUL TARGETING SELETTIVO MEDIATO DA NANOCARRIER E SI FOCALIZZA SULLO SFRUTTAMENTO DELLE PROPRIETA MULTIMODALI DI QUESTI COSTRUTTI, SUL LORO ACCUMULO NEI TESSUTI D?INTERESSE O PER RICONOSCIMENTO SELETTIVO DI UNITA TARGETING O VIA INTERNALIZZAZIONE IN CELLULE DEL SISTEMA IMMUNITARIO, SULLA LORO CAPACITA DI FUNZIONARE COME AGENTI DI CONTRASTO PER IMAGING E DI ESSERE ATTIVATI DA CAMPI MAGNETICI A BASSA FREQUENZA E/O IMPULSI LASER, FUNZIONANDO DA MEDIATORI IPERTERMICI. NEGLI ULTIMI ANNI CERICOL HA PROGREDITO NEL SUPERAMENTO DELLO STATO DELL?ARTE SVILUPPANDO UNA TECNICA INNOVATIVA, PERSONALIZZABILE SUL SINGOLO PAZIENTE E APPLICABILE AI FINI DIAGNOSTICI E TERAPEUTICI CON NOTEVOLE SPECIFICITA PER DIVERSE PATOLOGIE. NEL PRESENTE (Italian)
0 references
THE PROJECT AIMS TO OVERCOME TECHNOLOGICAL PROBLEMS IN THE DEVELOPMENT OF NEW DIAGNOSTIC AND THERAPEUTIC STRATEGIES FOR DISEASES WITH A HIGH SOCIAL IMPACT, SUCH AS MELANOMA AND MULTIPLE SCLEROSIS. THE IDEA IS BASED ON THE DEVELOPMENT OF NEW TECHNIQUES FOR CELL ENGINEERING AND/OR SELECTIVE TARGETING BY NANOCARRIER AND FOCUSES ON THE USE OF THE OWN MULTIMODAL PROPERTIES OF THESE CONSTRUCTS, THEIR ACCUMULATION IN THE TISSUES D? INTEREST, OR FOR SELECTIVE RECOGNITION OF TARGETING OR INTERNALISATION IN CELLS OF THE IMMUNE SYSTEM, THEIR ABILITY TO OPERATE AS LAW ENFORCEMENT AGENTS FOR IMAGING AND TO BE OPERATED BY LOW FREQUENCY MAGNETIC FIELDS AND/OR LASER PULSES, FUNCTIONING OF THE IPERTERMBICI MEDIATORS. IN THE LAST FEW YEARS, ERCOL HAS MADE PROGRESS IN OVERCOMING THE STATE OF THE ART, DEVELOPING AN INNOVATIVE TECHNIQUE, WHICH CAN BE CUSTOMISABLE ON THE INDIVIDUAL PATIENT AND WHICH IS APPLICABLE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES WITH A REMARKABLE SPECIFICATION FOR SEVERAL DISEASES. IN THE PRESENT (English)
0 references
Identifiers
D56G15001390009
0 references